Outcomes from COVID-19 Clinical Trials in Hospitalized Patients: Seeking the Truth That Matters.
作者信息
Griffith David M, Walsh Timothy S
机构信息
Usher Institute University of Edinburgh Edinburgh, United Kingdom.
出版信息
Am J Respir Crit Care Med. 2022 Sep 15;206(6):659-660. doi: 10.1164/rccm.202205-0907ED.
Abstract
摘要
相似文献
1
Outcomes from COVID-19 Clinical Trials in Hospitalized Patients: Seeking the Truth That Matters.住院患者新冠病毒疾病临床试验的结果：探寻重要的真相。
Am J Respir Crit Care Med. 2022 Sep 15;206(6):659-660. doi: 10.1164/rccm.202205-0907ED.
2
Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.COVID-19 住院成人患者使用伊马替尼的安全性和疗效：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Oct 28;21(1):897. doi: 10.1186/s13063-020-04819-9.
3
Clinical Characteristics and Outcomes Among Adults Hospitalized with Laboratory-Confirmed SARS-CoV-2 Infection During Periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant Predominance - One Hospital, California, July 15-September 23, 2021, and December 21, 2021-January 27, 2022.2021 年 7 月 15 日至 9 月 23 日和 2021 年 12 月 21 日至 2022 年 1 月 27 日期间，加利福尼亚州一家医院因实验室确诊的 SARS-CoV-2 感染住院的成年人的临床特征和结局，期间 B.1.617.2（德尔塔）和 B.1.1.529（奥密克戎）变异株占主导地位。
MMWR Morb Mortal Wkly Rep. 2022 Feb 11;71(6):217-223. doi: 10.15585/mmwr.mm7106e2.
4
Hormonal intervention for the treatment of veterans with COVID-19 requiring hospitalization (HITCH): a multicenter, phase 2 randomized controlled trial of best supportive care vs best supportive care plus degarelix: study protocol for a randomized controlled trial.针对需要住院治疗的 COVID-19 退伍军人的激素干预（HITCH）：一项多中心、2 期随机对照试验，比较最佳支持治疗与最佳支持治疗加地加瑞克：一项随机对照试验的研究方案。
Trials. 2021 Jul 5;22(1):431. doi: 10.1186/s13063-021-05389-0.
5
Post-COVID-19 Symptoms 2 Years After SARS-CoV-2 Infection Among Hospitalized vs Nonhospitalized Patients.SARS-CoV-2 感染后 2 年住院与非住院患者的新冠后症状。
JAMA Netw Open. 2022 Nov 1;5(11):e2242106. doi: 10.1001/jamanetworkopen.2022.42106.
6
Severity of Disease Among Adults Hospitalized with Laboratory-Confirmed COVID-19 Before and During the Period of SARS-CoV-2 B.1.617.2 (Delta) Predominance - COVID-NET, 14 States, January-August 2021.成人因实验室确诊的 COVID-19 住院的严重程度在 SARS-CoV-2 B.1.617.2（Delta）流行之前和期间-COVID-NET，14 个州，2021 年 1 月至 8 月。
MMWR Morb Mortal Wkly Rep. 2021 Oct 29;70(43):1513-1519. doi: 10.15585/mmwr.mm7043e1.
7
SARS-CoV-2 in pregnancy: characteristics and outcomes of hospitalized and non-hospitalized women due to COVID-19.SARS-CoV-2 在妊娠中的表现：因 COVID-19 住院和未住院的女性的特征和结局。
J Matern Fetal Neonatal Med. 2022 Jul;35(14):2648-2654. doi: 10.1080/14767058.2020.1793320. Epub 2020 Jul 20.
8
Clinical manifestations and disease severity of SARS-CoV-2 infection among infants in Canada.加拿大婴儿中严重急性呼吸综合征冠状病毒 2 感染的临床表现和疾病严重程度。
PLoS One. 2022 Aug 24;17(8):e0272648. doi: 10.1371/journal.pone.0272648. eCollection 2022.
9
Incidentally Detected SARS-COV-2 Among Hospitalized Patients in Los Angeles County, August to October 2020.2020 年 8 月至 10 月，洛杉矶县住院患者中偶然检出 SARS-COV-2。
J Hosp Med. 2021 Aug;16(8):480-483. doi: 10.12788/jhm.3641.
10
Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19-Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity - Nine States, January-September 2021.2021 年 1 月至 9 月，九个州感染诱导或 mRNA 疫苗诱导的 SARS-CoV-2 免疫的具有 COVID-19 样疾病住院成人的实验室确诊 COVID-19。
MMWR Morb Mortal Wkly Rep. 2021 Nov 5;70(44):1539-1544. doi: 10.15585/mmwr.mm7044e1.
本文引用的文献
1
Evaluating Primary Endpoints for COVID-19 Therapeutic Trials to Assess Recovery.评估 COVID-19 治疗试验的主要终点以评估康复情况。
Am J Respir Crit Care Med. 2022 Sep 15;206(6):730-739. doi: 10.1164/rccm.202112-2836OC.
2
Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses.瑞德西韦和其他三种药物治疗 COVID-19 住院患者：世卫组织团结随机试验的最终结果和更新的荟萃分析。
Lancet. 2022 May 21;399(10339):1941-1953. doi: 10.1016/S0140-6736(22)00519-0. Epub 2022 May 2.
3
Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3).新型 SARS-CoV-2 抗病毒药物试验的国际、多臂、多阶段平台主方案的设计与实施：COVID-19 住院患者的治疗（TICO/ACTIV-3）。
Clin Trials. 2022 Feb;19(1):52-61. doi: 10.1177/17407745211049829. Epub 2021 Oct 10.
4
Core Outcome Measures for Trials in People With Coronavirus Disease 2019: Respiratory Failure, Multiorgan Failure, Shortness of Breath, and Recovery.新型冠状病毒病 2019 患者临床试验的核心结局指标：呼吸衰竭、多器官衰竭、呼吸急促和康复。
Crit Care Med. 2021 Mar 1;49(3):503-516. doi: 10.1097/CCM.0000000000004817.
5
Core Outcomes Set for Trials in People With Coronavirus Disease 2019.新型冠状病毒病 2019 患者临床试验的核心结局集。
Crit Care Med. 2020 Nov;48(11):1622-1635. doi: 10.1097/CCM.0000000000004585.
6
Core Outcome Set for Clinical Trials of COVID-19 Based on Traditional Chinese and Western Medicine.基于中西医结合的新型冠状病毒肺炎临床试验核心结局集
Front Pharmacol. 2020 May 25;11:781. doi: 10.3389/fphar.2020.00781. eCollection 2020.
7
A minimal common outcome measure set for COVID-19 clinical research.用于 COVID-19 临床研究的最小通用结局指标集。
Lancet Infect Dis. 2020 Aug;20(8):e192-e197. doi: 10.1016/S1473-3099(20)30483-7. Epub 2020 Jun 12.
8
Remdesivir for the Treatment of Covid-19 - Final Report.瑞德西韦治疗 COVID-19 的疗效 - 最终报告。
N Engl J Med. 2020 Nov 5;383(19):1813-1826. doi: 10.1056/NEJMoa2007764. Epub 2020 Oct 8.
9
Core Outcome Set for Clinical Trials on Coronavirus Disease 2019 (COS-COVID).2019年冠状病毒病临床试验核心结局集（COS-COVID）
Engineering (Beijing). 2020 Oct;6(10):1147-1152. doi: 10.1016/j.eng.2020.03.002. Epub 2020 Mar 18.
Zotero 插件